SALT LAKE CITY, March 14, 2019 /PRNewswire/ -- Lipocine Inc.
(NASDAQ: LPCN), a specialty pharmaceutical company, announced today
that it has been selected to present LPCN 1144 clinical results as
part of ENDO 2019. The presentation will highlight the
therapeutic potential of LPCN 1144 in non-alcoholic fatty liver
disease ("NAFLD") and non-alcoholic steatohepatitis
("NASH"). ENDO 2019 is being held March 23rd – 26th in
New Orleans, LA.
Presentation
Details
|
|
Title:
|
Therapeutic Potential
of LPCN 1144 in NAFLD and NASH
|
Poster
Number:
|
Poster Board #
SAT-LB004
|
Date:
|
Saturday, March
23rd
|
Location:
|
Ernest N. Morial
Convention Center, New Orleans, LA
|
Time:
|
1:00-3:00
pm
|
About Lipocine
Lipocine Inc. is a specialty pharmaceutical company
developing innovative pharmaceutical products for use in men's and
women's health using its proprietary drug delivery technologies.
Lipocine's clinical development pipeline includes four development
programs TLANDO, LPCN 1144, LPCN 1111 and LPCN 1107. TLANDO, a
novel oral prodrug of testosterone containing testosterone
undecanoate, is designed to help restore normal testosterone levels
in hypogonadal men. TLANDO received a Complete Response Letter from
the FDA on May 8, 2018. LPCN 1144, an
oral prodrug of bioidentical testosterone, is being developed as a
treatment of non-alcoholic steatohepatitis ("NASH") and has
recently completed a proof-of-concept clinical study. LPCN 1111, a
novel oral prodrug of testosterone, originated and is being
developed by Lipocine as a next-generation oral testosterone
product with potential for once-daily dosing and is currently in
Phase 2 testing. LPCN 1107 is potentially the first oral
hydroxyprogesterone caproate product candidate indicated for the
prevention of recurrent preterm birth and has been granted orphan
drug designation by the FDA. An End of Phase 2 meeting with the FDA
has been completed. For more information, please visit
www.lipocine.com
Forward-Looking Statements
This release contains "forward looking statements" that are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and include statements that are not
historical facts regarding Lipocine's product candidates and
related clinical trials and the FDA review process relating to its
product candidates, the path to approvability by the FDA of
Lipocine's development programs, the potential uses and benefits of
our product candidates, including LPCN 1144, and our product
development efforts. Investors are cautioned that all such
forward-looking statements involve risks and uncertainties,
including, without limitation, the risks that the FDA will not
approve any of our products, risks related to our products,
expected product benefits not being realized, clinical and
regulatory expectations and plans not being realized, new
regulatory developments and requirements, risks related to the FDA
approval process including the receipt of regulatory approvals, the
results and timing of clinical trials, patient acceptance of
Lipocine's products, the manufacturing and commercialization of
Lipocine's products, and other risks detailed in Lipocine's filings
with the SEC, including, without limitation, its Form 10-K and
other reports on Forms 8-K and 10-Q, all of which can be obtained
on the SEC website at www.sec.gov. Lipocine assumes no obligation
to update or revise publicly any forward-looking statements
contained in this release, except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lipocine-announces-presentation-highlighting-therapeutic-potential-of-lpcn-1144-in-nafld-and-nash-selected-for-endo-2019-300812179.html
SOURCE Lipocine Inc.